2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Molecular Testing, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Non-Biological Therapies, Pharmacology, Adverse Events, Artificial Intelligence (AI), Machine Learning, Natural Language Processing, Biological Processes, Pathogenesis, Genomics, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Quality of Care, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Measurable Residual Disease, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Registries, Study Population, Human, Adult, Young Adult
PAPER

3912 Wavespan-006: A phase 2, open-label, multicenter study to determine the safety, tolerability, and efficacy of MK-1045, a novel CD19 × CD3 T-cell engager, in participants with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL)

Farrukh T Awan, M.D.M.S.,M.B.A., Jheremy Reyes, MD2, Kenny Mauricio Gálvez, MD3, Francesc Bosch4, Cristina De Ramón, MD5, Carmen Martínez Chamorro6, Fatima Miras7, Jose Luis Luis Viñuela8, Raimundo Gazitua Pepper9, Sergio Portiño10, Federico Lussana, MD, PhD11, Simona Sica, MD, PhD12, Sarah Matarasso Greenfeld13, Ohad Benjamini, MD14, Nurit Horesh, MD15, Yair Herishanu, Prof16, Liron Hofstetter, MD17, Tian He18, Ima Paydar, MD19, Mohammed Z.H. Farooqui, DO20, Nitin Jain, MD21
1 UT Southwestern Medical Center, Dallas, Texas, United States
2 Los Cobos Medical Center, Bogotá, Colombia
3 Hospital Pablo Tobón Uribe, Medellín, Colombia
4 Vall d’Hebron University Hospital, Barcelona, Spain
5 Hospital Universitario de Salamanca, Salamanca, Spain
6 Hospital Universitario Quirónsalud Pozuelo, Madrid, Spain, Universidad Europea de Madrid, Madrid, Spain
7 Hospital Universitario 12 de Octubre, Madrid, Spain
8 Clínica Inmunocel and Laboratorio Inmunocel, Santiago, Chile
9 Instituto Oncológico Fundación Arturo López Pérez (FALP), Providencia, Chile
10 Bradford Hill Clinical Research Center, Santiago, Chile, Finis Terrae University, Faculty of Medicine, Santiago, Chile
11 Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy, Department of Oncology and Hematology, University of Milan, Milan, Italy
12 Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy, Università Cattolica Sacro Cuore, Rome, Italy
13 Shaare Zedek Medical Center, Jerusalem, Israel
14 Chaim Sheba Medical Center, Ramat Gan, Israel
15 Rambam Health Care Campus, Haifa, Israel
16 Sourasky Medical Center, Tel Aviv, Israel
17 Beilinson Hospital, Rabin Medical Center, Petah-Tikva, Israel
18 Merck & Co., Inc., Rahway, New Jersey, United States
19 Merck & Co., Inc., Rahway, New Jersey, United States
20 Merck & Co., Inc., Rahway, New Jersey, United States
21 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Background and Significance: CD19 is an attractive therapeutic target in B-cell malignancies due to its broad expression profile and low rate of downregulation in neoplastic B cells in leukemias and lymphomas. Despite advances in CD19-directed CAR T-cell therapies, which have demonstrated clinical activity across multiple B-cell malignancies, there remains a high unmet need for new therapeutic options, especially for R/R CLL and SLL. MK-1045, an investigational humanized bispecific IgG4 CD19 × CD3 T-cell engager, has demonstrated early evidence of antitumor activity with manageable safety in participants with R/R B-cell malignancies, including acute lymphoblastic leukemia, diffuse large B-cell lymphoma, and follicular lymphoma. Here, we describe the WaveSpan-006 study (NCT07709000), an ongoing, multicenter, open-label, phase 2 study designed to evaluate the safety, tolerability, and efficacy of MK-1045 monotherapy in participants with R/R CLL and SLL.

Study Design and Methods: Eligible participants are adults aged ≥18 years with histologically confirmed R/R CLL/SLL per 2018 iwCLL criteria, CD19-positive disease by local flow cytometry, active disease requiring treatment, and prior therapy with both a BTK inhibitor and a BCL2 inhibitor. Additional inclusion criteria include ECOG performance status score of 0-2, adequate organ function, oxygen saturation >92% without supplemental oxygen, and measurable or objectively evaluable disease, including ≥1 iwCLL response-assessable parameter for CLL or ≥1 measurable nodal lesion ≥15 mm by CT or MRI for SLL. Key exclusion criteria include serious cardiovascular or cerebrovascular disease, clinically relevant or active central nervous system disease, Richter transformation, and prior CAR T-cell therapy within 12 weeks before first dose of study treatment. The study will comprise 2 parts: part 1 will enroll approximately 45 participants for dose finding, and part 2 will enroll approximately 15 participants for dose expansion at the preliminary recommended dose. MK-1045 will be administered intravenously using step-up dosing in cycle 1, with priming dose 1 on day 1, priming dose 2 on day 4, an intermediate dose on day 8, and weekly target dosing thereafter. Planned target dose levels are 40-90 mg. Dose finding will follow a Bayesian Optimal Interval design with a target dose-limiting toxicity rate of 30%. Participants may continue treatment for approximately 2 years or until protocol-defined discontinuation criteria are met; those who complete ≥3 cycles and achieve a complete response may switch to every-2-week dosing at the investigator’s discretion and after sponsor consultation. The primary end points are safety and tolerability in part 1, including dose-limiting toxicities, adverse events, and adverse events leading to treatment discontinuation, and objective response rate in parts 1 and 2 per 2018 iwCLL criteria by blinded independent central review. Secondary end points include safety and tolerability in part 2 and duration of response, pharmacokinetics, and antidrug and neutralizing antibody formation (if applicable) in parts 1 and 2. Exploratory end points include minimal residual disease negativity, time to next treatment, overall survival, and progression-free survival for parts 1 and 2 and patient-reported outcomes for part 2. Efficacy and safety will be assessed in the all-participants-as-treated population. Adverse events will be monitored throughout the study and graded in severity per National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0, American Society for Transplant and Cellular Therapy (ASTCT) grading for cytokine-release syndrome and ICANS, and iwCLL 2018 criteria for hematologic adverse events. Objective response rate and its 95% CI will be estimated using the exact binomial Clopper-Pearson method, and duration of response, progression-free survival, and overall survival will be estimated using the Kaplan-Meier method. No formal hypothesis testing or multiplicity adjustment is planned. Recruitment is currently underway.

Farrukh T Awan, M.D.M.S.,M.B.A.: Actinium Pharmaceutical - Research Funding; Abbvie - Research Funding; Pharmacyclics - Research Funding; Caribou Biosciences - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony); Loxo Oncology - Consultancy (Includes expert testimony); Ascentage - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); Genentech - Consultancy (Includes expert testimony); Invivyd - Consultancy (Includes expert testimony); Pierre Fabre - Consultancy (Includes expert testimony); Miltenyi - Consultancy (Includes expert testimony); Abbvie - Consultancy (Includes expert testimony); Dava Oncology - Consultancy (Includes expert testimony); BeOne - Consultancy (Includes expert testimony); Genmab - Consultancy (Includes expert testimony); Adaptive Biotechnologies - Consultancy (Includes expert testimony)